Pharmacokinetics Characteristics of Clomiphene Citrate in Patients with Polycystic Ovary Syndrome (PCOS)

Pharmacokinetics Characteristics of Clomiphene Citrate in Patients with Polycystic Ovary Syndrome (PCOS)

BACKGROUND AND OBJECTIVE: There are no pharmacokinetic data on CC isomers zuclomiphene (Zu) and enclomiphene (En) in patients receiving the drug, mainly women with polycystic ovary disease (PCOS). Thus, the main purpose of this study was to characterize the pharmacokinetics of Zu and En isomers and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: N Mirhosseini, N Najafi, MR Shiran, AA Moghadamnia
Formato: article
Lenguaje:EN
FA
Publicado: Babol University of Medical Sciences 2011
Materias:
infertility
polycystic ovary disease
clomiphene citrate
zuclomiphene
enclomiphene
Medicine
R
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/212a01a30344458c9797037c94f8c35c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:212a01a30344458c9797037c94f8c35c
record_format dspace
spelling oai:doaj.org-article:212a01a30344458c9797037c94f8c35c2021-11-10T08:56:57ZPharmacokinetics Characteristics of Clomiphene Citrate in Patients with Polycystic Ovary Syndrome (PCOS)1561-41072251-7170https://doaj.org/article/212a01a30344458c9797037c94f8c35c2011-11-01T00:00:00Zhttp://jbums.org/article-1-3920-en.htmlhttps://doaj.org/toc/1561-4107https://doaj.org/toc/2251-7170BACKGROUND AND OBJECTIVE: There are no pharmacokinetic data on CC isomers zuclomiphene (Zu) and enclomiphene (En) in patients receiving the drug, mainly women with polycystic ovary disease (PCOS). Thus, the main purpose of this study was to characterize the pharmacokinetics of Zu and En isomers and their intersubject variability, for the first time, in anovular patients with PCOS after a single oral administration of CC.METHODS: Nine women with infertility and PCOS who referred to the infertility clinic were included in this study. After getting consent of patients and ethical approval from the University ethics committee, they received clomiphene citrate 50 mg on the first day of their menstrual cycle. LH, FSH and prolactin levels were measured before and after medication. Plasma concentrations of Zu and En were measured in the patients from the second day of their menstrual cycle (day 1 of dosing) up to 21 days. FINDINGS: The mean (± coefficient of variation) of Cmax, tmax, and AUC of Zu was 15±41 ng/mL, 7±87 h, and 1289±34 ng/mL.h (AUC0-456 h), and that of En was 15±18 ng/mL, 3±68 h, and 65±35 ng/ml.h (AUC0-72 h), respectively.CONCLUSION: These parameters appeared to be different for Zu from those reported previously in healthy participant the pharmacokinetic parameters of En in patients with polycystic ovary syndrome were not generally different from the healthy subjects.N Mirhosseini,N Najafi,MR Shiran,AA MoghadamniaBabol University of Medical Sciencesarticleinfertilitypolycystic ovary diseaseclomiphene citratezuclomipheneenclomipheneMedicineRMedicine (General)R5-920ENFAMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, Vol 13, Iss 6, Pp 14-20 (2011)
institution DOAJ
collection DOAJ
language EN
FA
topic infertility
polycystic ovary disease
clomiphene citrate
zuclomiphene
enclomiphene
Medicine
R
Medicine (General)
R5-920
spellingShingle infertility
polycystic ovary disease
clomiphene citrate
zuclomiphene
enclomiphene
Medicine
R
Medicine (General)
R5-920
N Mirhosseini,
N Najafi,
MR Shiran,
AA Moghadamnia
Pharmacokinetics Characteristics of Clomiphene Citrate in Patients with Polycystic Ovary Syndrome (PCOS)
description BACKGROUND AND OBJECTIVE: There are no pharmacokinetic data on CC isomers zuclomiphene (Zu) and enclomiphene (En) in patients receiving the drug, mainly women with polycystic ovary disease (PCOS). Thus, the main purpose of this study was to characterize the pharmacokinetics of Zu and En isomers and their intersubject variability, for the first time, in anovular patients with PCOS after a single oral administration of CC.METHODS: Nine women with infertility and PCOS who referred to the infertility clinic were included in this study. After getting consent of patients and ethical approval from the University ethics committee, they received clomiphene citrate 50 mg on the first day of their menstrual cycle. LH, FSH and prolactin levels were measured before and after medication. Plasma concentrations of Zu and En were measured in the patients from the second day of their menstrual cycle (day 1 of dosing) up to 21 days. FINDINGS: The mean (± coefficient of variation) of Cmax, tmax, and AUC of Zu was 15±41 ng/mL, 7±87 h, and 1289±34 ng/mL.h (AUC0-456 h), and that of En was 15±18 ng/mL, 3±68 h, and 65±35 ng/ml.h (AUC0-72 h), respectively.CONCLUSION: These parameters appeared to be different for Zu from those reported previously in healthy participant the pharmacokinetic parameters of En in patients with polycystic ovary syndrome were not generally different from the healthy subjects.
format article
author N Mirhosseini,
N Najafi,
MR Shiran,
AA Moghadamnia
author_facet N Mirhosseini,
N Najafi,
MR Shiran,
AA Moghadamnia
author_sort N Mirhosseini,
title Pharmacokinetics Characteristics of Clomiphene Citrate in Patients with Polycystic Ovary Syndrome (PCOS)
title_short Pharmacokinetics Characteristics of Clomiphene Citrate in Patients with Polycystic Ovary Syndrome (PCOS)
title_full Pharmacokinetics Characteristics of Clomiphene Citrate in Patients with Polycystic Ovary Syndrome (PCOS)
title_fullStr Pharmacokinetics Characteristics of Clomiphene Citrate in Patients with Polycystic Ovary Syndrome (PCOS)
title_full_unstemmed Pharmacokinetics Characteristics of Clomiphene Citrate in Patients with Polycystic Ovary Syndrome (PCOS)
title_sort pharmacokinetics characteristics of clomiphene citrate in patients with polycystic ovary syndrome (pcos)
publisher Babol University of Medical Sciences
publishDate 2011
url https://doaj.org/article/212a01a30344458c9797037c94f8c35c
work_keys_str_mv AT nmirhosseini pharmacokineticscharacteristicsofclomiphenecitrateinpatientswithpolycysticovarysyndromepcos
AT nnajafi pharmacokineticscharacteristicsofclomiphenecitrateinpatientswithpolycysticovarysyndromepcos
AT mrshiran pharmacokineticscharacteristicsofclomiphenecitrateinpatientswithpolycysticovarysyndromepcos
AT aamoghadamnia pharmacokineticscharacteristicsofclomiphenecitrateinpatientswithpolycysticovarysyndromepcos
_version_ 1718440263525859328

Ejemplares similares